Biophytis Receives FDA IND Clearance for COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure
July 02, 2020 11:02 ET
|
Biophytis SA
PARIS and CAMBRIDGE, Mass., July 02, 2020 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company specialized in the development of drug candidates...
Biophytis Announces Results of 2019 Annual General Meeting of Shareholders
June 28, 2019 12:29 ET
|
BIOPHYTIS SA
All resolutions within the competence of the Ordinary General Meeting adoptedSecond notice to reconvene the Extraordinary General Meeting to be held in the coming weeks PARIS and CAMBRIDGE, Mass.,...
Biophytis Enters into a Collaboration with the French Muscular Dystrophy Association (AFM-Telethon)
June 13, 2019 08:23 ET
|
BIOPHYTIS SA
Provides funding for additional preclinical experiments and for the MYODA preparations for the clinical study in Duchenne muscular dystrophy (DMD) PARIS and CAMBRIDGE, Mass., June 13, 2019 (GLOBE...
Biophytis Expands Daniel Schneiderman’s Role to Group Chief Financial Officer
June 07, 2019 14:13 ET
|
BIOPHYTIS SA
PARIS and CAMBRIDGE, Mass., June 07, 2019 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics for...
Biophytis Announces Publication of its 2018 Annual Report
May 22, 2019 14:55 ET
|
BIOPHYTIS SA
Files 2018 Annual Report with the AMFProvides first quarter 2019 financial statementsEnters into intellectual property agreement with Stanislas Veillet PARIS and CAMBRIDGE, Mass., May 22, 2019 ...
Biophytis Files Registration Statement for Proposed Initial Public Offering in the United States
May 22, 2019 10:31 ET
|
BIOPHYTIS SA
PARIS and CAMBRIDGE, Mass., May 22, 2019 (GLOBE NEWSWIRE) -- Biophytis (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics for...
Biophytis Reports Annual 2018 Financial Results and Provides Operational Update
March 12, 2019 02:00 ET
|
BIOPHYTIS SA
Clinical execution and advancement of our SARA program, including initiation of the SARA-INT Phase 2b clinical trial for sarcopeniaLaunch of our MYODA program for Duchenne muscular dystrophy...
Biophytis Announces Three Oral and One Poster Presentations at the 2019 International Conference on Frailty and Sarcopenia Research
February 18, 2019 01:00 ET
|
BIOPHYTIS SA
PARIS, Feb. 18, 2019 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of novel therapeutics for age-related...
BIOPHYTIS Strengthens its Senior Management Team and Continues its Expansion in the United States
December 17, 2018 01:30 ET
|
BIOPHYTIS SA
PARIS, Dec. 17, 2018 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris : ALBPS), a biotechnology company developing drug candidates to reduce disabilities caused by age-related and genetic...
BIOPHYTIS Announces One Oral Presentation and Two Poster Presentations at the 11th International Conference on Cachexia, Sarcopenia and Muscle Wasting
December 07, 2018 13:47 ET
|
BIOPHYTIS SA
PARIS, Dec. 07, 2018 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company developing first-in-class drug candidates for the treatment of age-related...